Literature DB >> 2458833

Stromal fibronectin staining pattern and metastasizing ability of human breast carcinoma.

L Christensen1, M Nielsen, J Andersen, I Clemmensen.   

Abstract

The peripheral stromal fibronectin (FN) staining patterns of invasive breast carcinomas (IBC) from 77 women were compared to the aggressivity of the tumors, which in each case had been determined through a complete clinical follow-up and autopsy investigation. Polyclonal, monospecific rabbit antibody to human FN was applied on formalin-fixed, paraffin-embedded tissue sections using the peroxidase-antiperoxidase staining technique. An FN-positive staining reaction was defined as a constant, diffuse, or pericellular demarcation of FN-positive fibers surrounding tumor cells at the invasive border. In lack of such a staining pattern, FN-negative staining was recorded. The FN-positive staining reaction was significantly associated with a low metastatic potential and appeared in a multivarians analysis to be an excellent prognostic factor, which surpassed other known parameters, such as clinical stage, histological type or grade, and lymph node status. 27 out of 31 women, who died without evidence of metastatic spread, had FN-positive IBC (87%) in contrast to women with metastatic disease, where only 15 out of 46 had FN-positive tumors (33%). An extensive histopathological examination of the contralateral breast revealed in this latter group a high rate of second primaries (22/46), which might have been responsible for the metastatic spread. If these women with bilateral IBC were excluded, only three metastasizing tumors with a FN-positive staining pattern remained, suggesting that the prognostic value of the FN-staining pattern along the invasive border of IBC might be even higher than anticipated from this study.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458833

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Mislocalized scaffolding by the Na-H exchanger NHE1 dominantly inhibits fibronectin production and TGF-beta activation.

Authors:  Anastasios Karydis; Maite Jimenez-Vidal; Sheryl P Denker; Diane L Barber
Journal:  Mol Biol Cell       Date:  2009-02-18       Impact factor: 4.138

2.  Cytoskeletal and extracellular matrix proteins as markers for metastatic triple negative breast cancer.

Authors:  Mohammed Elimam Ahamed Mohammed; Nuha Mohammed Elhassan
Journal:  J Int Med Res       Date:  2019-10-11       Impact factor: 1.671

Review 3.  TGFBR1*6A as a modifier of breast cancer risk and progression: advances and future prospects.

Authors:  Kojo Agyemang; Allan M Johansen; Grayson W Barker; Michael J Pennison; Kimberly Sheffield; Hugo Jimenez; Carl Blackman; Sambad Sharma; Patrick A Fordjour; Ravi Singh; Katherine L Cook; Hui-Kuan Lin; Wei Zhang; Hui-Wen Lo; Kounosuke Watabe; Peiqing Sun; Carl D Langefeld; Boris Pasche
Journal:  NPJ Breast Cancer       Date:  2022-07-19

4.  Differences in tetranectin immunoreactivity between benign and malignant breast tissue.

Authors:  L Christensen; I Clemmensen
Journal:  Histochemistry       Date:  1991

5.  TGFBR1*6A enhances the migration and invasion of MCF-7 breast cancer cells through RhoA activation.

Authors:  Diana S Rosman; Sharbani Phukan; Chiang-Ching Huang; Boris Pasche
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

6.  Colonial morphology of tumour cells and susceptibility to cytolysis by tumour necrosis factor. The role of cellular fibronectin deposition in the extracellular matrix.

Authors:  M L Neale; N Matthews
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

7.  Loss of VLA-2 collagen receptor in breast carcinoma, facilitating invasion and metastasis.

Authors:  K Arihiro; K Inai; K Kurihara; S Takeda; M Kaneko; K Kuroi; T Toge
Journal:  Jpn J Cancer Res       Date:  1993-07

Review 8.  Fibronectin in Cancer: Friend or Foe.

Authors:  Tsung-Cheng Lin; Cheng-Han Yang; Li-Hsin Cheng; Wen-Tsan Chang; Yuh-Rong Lin; Hung-Chi Cheng
Journal:  Cells       Date:  2019-12-20       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.